Precision medicine is a rapidly evolving approach of tailoring therapeutic interventions to the individual molecular features of a patient and/or their disease, that moves beyond the conventional approach of stratifying patients into treatment groups based on phenotypic markers.1
Biomarker testing can unlock essential information for complete diagnosis and appropriate treatment planning.1–4
You can also find further information and education about genomics testing by participating in the HEE Genomics Education Programme.
More information can be found here.
Virtual Pathology and Genomics Lab Tour
Diagnostic services are rapidly evolving in the UK, with additional molecular and genomic tests, new technologies and broader profiling than previously available.
Prof. Louise Jones (Professor of Breast Pathology at Bart’s Hospital in London, and Pathology Lead for the North Thames Genomic Laboratory Hub [GLH]) and Dr Mike Hubank (Head of Clinical Genomics at The Royal Marsden Hospital in London and Scientific Director of the North Thames GLH) provide an introduction to the Novartis Virtual Pathology and Genomics Laboratory Tour, highlighting the important roles of both pathologists and molecular scientists in the diagnostic sample pathway.
They will introduce your lab tour guide SAL (sentient artificial lifeform), the Novartis animated avatar, who will guide you through this virtual interactive tour allowing you to explore techniques and processes inside the laboratory, from sample preparation, to histopathology, to downstream molecular and genomic testing.
Click below to begin your tour!
Only available for desktops/laptops and larger Android tablets.
Not available on this device, please view on a desktop or larger tablet.
You can also find further information and education about genomics testing by participating in the HEE Genomics Education Programme.
More information can be found here.
Precision medicine: A healthcare approach with the primary aim of identifying which interventions are likely to be of most benefit to which patients based upon the features of the individual and their disease.1
Mutation/genomic mutation: A permanent alteration in the DNA sequence that may be somatic (acquired during an individual’s lifetime) or germline (inherited).1
Actionable genomic alteration: Includes both targetable alterations (that encode an altered protein against which a medicine exists) and alterations that cannot be directly targeted but that lead to dysregulation of a pathway in which there are possible targets.1
References
- Yates LR, et al. Ann Oncol 2018;29(1):30–35.
- Planchard D, et al. Ann Oncol 2018;29 Suppl 4:iv192–iv237.
- Michielin O, et al. Ann Oncol 2019;30(12):1884–1901.
- Gennari A, et al. Ann Oncol 2021;32(12):1475–1495.